TY - JOUR
T1 - Resistance of aspirin during and after pregnancy: A longitudinal cohort study
AU - bij de Weg, Jeske M.
AU - Abheiden, Carolien N. H.
AU - Fuijkschot, Wessel W.
AU - Harmsze, Ankie M.
AU - de Boer, Marjon A.
AU - Thijs, Abel
AU - de Vries, Johanna I. P.
PY - 2020/1
Y1 - 2020/1
N2 - Objectives: The objective of this study is to investigate possible changes in aspirin resistance during and after pregnancy over time. Study design: A longitudinal cohort study in obstetric high risk women with an indication for aspirin usage during pregnancy to prevent placenta mediated pregnancy complications. Main outcome measures: Aspirin resistance measured in the first, second and third trimester of pregnancy and at least three months postpartum by four complementary test: PFA-200, VerifyNow®, Chronolog light transmission aggregometry (Chronolog LTA) and serum thromboxane B2 (TxB2) level measurements. Correlation between the devices was investigated. Results: In total, 23 pregnant women participated in the present study. Aspirin resistance according to the PFA-200, VerifyNow®, Chronolog LTA and serum TxB2, was 30.4%, 17.4%, 26.1% and 23.8% respectively. Resistance by any device was 69.6%. Aspirin resistance measured by the VerifyNow®, Chronolog LTA, serum TxB2 and aspirin resistance by any device during pregnancy was demonstrated more frequently than aspirin resistance after pregnancy. Correlation between the different devices was weak. Conclusion: Aspirin resistance was found in a considerable part of the participants. Considerable variation between participants, within participants over time and between the different devices was found. Prevalence of aspirin resistance during pregnancy differs from after pregnancy. More research on aspirin resistance and clinical obstetric outcome is needed.
AB - Objectives: The objective of this study is to investigate possible changes in aspirin resistance during and after pregnancy over time. Study design: A longitudinal cohort study in obstetric high risk women with an indication for aspirin usage during pregnancy to prevent placenta mediated pregnancy complications. Main outcome measures: Aspirin resistance measured in the first, second and third trimester of pregnancy and at least three months postpartum by four complementary test: PFA-200, VerifyNow®, Chronolog light transmission aggregometry (Chronolog LTA) and serum thromboxane B2 (TxB2) level measurements. Correlation between the devices was investigated. Results: In total, 23 pregnant women participated in the present study. Aspirin resistance according to the PFA-200, VerifyNow®, Chronolog LTA and serum TxB2, was 30.4%, 17.4%, 26.1% and 23.8% respectively. Resistance by any device was 69.6%. Aspirin resistance measured by the VerifyNow®, Chronolog LTA, serum TxB2 and aspirin resistance by any device during pregnancy was demonstrated more frequently than aspirin resistance after pregnancy. Correlation between the different devices was weak. Conclusion: Aspirin resistance was found in a considerable part of the participants. Considerable variation between participants, within participants over time and between the different devices was found. Prevalence of aspirin resistance during pregnancy differs from after pregnancy. More research on aspirin resistance and clinical obstetric outcome is needed.
KW - Aspirin
KW - Drug resistance
KW - HELLP
KW - Pre-eclampsia
KW - Pregnancy
KW - Preventive therapy
UR - http://www.scopus.com/inward/record.url?scp=85076789860&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.preghy.2019.11.008
DO - https://doi.org/10.1016/j.preghy.2019.11.008
M3 - Article
C2 - 31865169
SN - 2210-7789
VL - 19
SP - 25
EP - 30
JO - Pregnancy Hypertension
JF - Pregnancy Hypertension
ER -